DEUTSCHE BANK AG\ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2020$1,042,000
-26.5%
1,082,000
-26.7%
0.00%0.0%
Q1 2020$1,417,000
+15.3%
1,476,000
+19.0%
0.00%
Q2 2018$1,229,000
-36.7%
1,240,000
-13.9%
0.00%
-100.0%
Q2 2017$1,943,0001,440,0000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2018
NameSharesValueWeighting ↓
Context Capital Management, LLC 25,388$23,544,0002.40%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 49,675,000$46,013,0001.22%
DeepCurrents Investment Group LLC 33,824,000$31,165,0000.93%
Aequim Alternative Investments LP 13,920,000$12,909,0000.50%
Maven Securities LTD 14,280,000$14,280,0000.46%
Saltoro Capital, LP 1,350,000$1,252,0000.44%
Baupost Group 30,000,000$27,640,0000.25%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,182,0000.12%
ZAZOVE ASSOCIATES LLC 1,250,000$1,163,0000.10%
HBK INVESTMENTS L P 22,500,000$20,832,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders